1. Maganti, H. et al. Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. Leuk. Res. 97, (2020).
2. Wan, B. A. et al. Revised 15-item MDS-specific frailty scale maintains prognostic potential. Leukemia (2020) doi:10.1038/s41375-020-01026-y.
3. Nazha, A. et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol. Blood Marrow Transplant. (2020) doi:10.1016/j.bbmt.2020.08.003.
4. Fulcher, J., Leung, E., Christou, G., Bredeson, C. & Sabloff, M. Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. Leukemia and Lymphoma vol. 61 2271–2273 (2020).
5. Altouri, S. et al. Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. Bone Marrow Transplantation vol. 55 1454–1456 (2020).
6. Starkman, R. et al. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia 34, 1394–1406 (2020).
7. Pi, L. et al. Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. Leuk. Res. 86, 106222 (2019).